Tianjin Key Laboratory of Retinal Functions and Diseases, Tianjin Branch of National Clinical Research Center for Ocular Disease, Eye Institute and School of Optometry, Tianjin Medical University Eye Hospital, No.251, Fukang Road, Nankai District, Tianjin, 300384, China.
The Eye Hospital, School of Ophthalmology and Optometry, Wenzhou Medical University, Wenzhou, Zhejiang, China.
BMC Ophthalmol. 2022 Jun 21;22(1):273. doi: 10.1186/s12886-022-02497-6.
This study aimed to investigate the clinical effectiveness of posterior scleral reinforcement(PSR) for the treatment of myopic traction maculopathy (MTM).
This was a prospective study of 32 eyes from 20 patients with MTM treated with PSR using genipin-cross-linked donor sclera. The length of the scleral strip used for the surgery was designed to be 1.5-times the axial length of the eye, whereas its width was 0.4-times the axial length of the eye. The optical coherence tomography images, spherical equivalent of refractive error, axial length, best corrected visual acuity, electroretinogram findings, and intraocular pressure of the patients were assessed postoperatively.
The mean duration of follow-up was 17.80 ± 8.74 months. The differences between the spherical equivalent of refractive error, best corrected visual acuity, axial length, and electroretinogram findings recorded preoperatively and those measured postoperatively were statistically significant (p < 0.05). The final reduction in axial length was 1.64 ± 0.85 mm. At the end of the follow-up, optical coherence tomography showed essential foveal reattachment in 30 eyes (93.75%), partial reattachment in two eyes (6.25%), and closure of macular holes in seven eyes (77.78%). No retinal detachment, vitreous haemorrhage, or other serious complications occurred following the surgery.
Posterior scleral reinforcement with genipin-cross-linked sclera showed safe and effective outcomes for the treatment of MTM during a follow-up period of at least one year.
11\12\2018, ChiCTR1800020012 .
本研究旨在探讨后巩膜加固术(PSR)治疗近视牵引性黄斑病变(MTM)的临床疗效。
这是一项前瞻性研究,共纳入 20 例(32 只眼)MTM 患者,均采用基因交联供体巩膜行 PSR。巩膜条的长度设计为眼轴的 1.5 倍,宽度为眼轴的 0.4 倍。术后评估患者的光学相干断层扫描图像、等效球镜屈光度、眼轴长度、最佳矫正视力、视网膜电图检查结果和眼压。
平均随访时间为 17.80±8.74 个月。术前与术后等效球镜屈光度、最佳矫正视力、眼轴长度和视网膜电图检查结果的差异均有统计学意义(p<0.05)。最终眼轴缩短 1.64±0.85mm。随访结束时,30 只眼(93.75%)光相干断层扫描显示黄斑中心凹完全再附着,2 只眼(6.25%)部分再附着,7 只眼(77.78%)黄斑裂孔闭合。术后无视网膜脱离、玻璃体积血等严重并发症发生。
基因交联巩膜后巩膜加固术治疗 MTM 至少 1 年的随访结果安全有效。
11\12\2018,ChiCTR1800020012。